Oct 17, 2022 05:25 PM (GMT+8) · EqualOcean
Kunshi Biotechnology (Chinese: 鲲石生物), provider of a technology platform for macrophage-based therapies of solid tumors, announced the completion of the angel round worth tens of millions of CNY recently. The round was invested conjointly by ASB Ventures (Chinese: 澳银资本) and Liman Caixiang (Chinese: 黎曼猜想). Liman Caixiang incubated the company and served as the exclusive financial advisor for this round. The funds will be used for the laboratory platform construction, pipeline R&D and pre-clinical trials, patent layout and the company operation. Founded in 2021, Kunshi Biotechnology focuses on the development and clinical application of macrophage drugs for solid tumors.